We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Immunoassay Evaluated for Detection of Helicobacter pylori

By LabMedica International staff writers
Posted on 02 Aug 2011
The efficacy of a new polyclonal enzyme immunoassay (EIA) for the detection of Helicobacter pylori antigen in feces has been determined. More...


The immunoassay has been compared with histology, rapid urease test, carbon-13 (13C)-urea breath test, and serology to determine the optimal cut-off value for screening a population at risk.

Scientists at Seoul National University (Seoul, Korea) prospectively enrolled 515 patients undergoing a routine health check-up. H. pylori infection was defined if at least two of four of the following tests: histology, rapid urease test, 13C-urea breath test, and serology, were positive. Stool samples were analyzed using a new polyclonal EIA stool antigen test, the EZ-STEP H. pylori, which was performed by the capture of polyclonal antibodies to H. pylori absorbed in microwells. The optimal cut-off value was determined by the receiver–operator characteristic curve. The diagnostic performance of each test was evaluated with regard to the histological diagnosis of atrophic gastritis (AG)/intestinal metaplasia (IM), degree of AG/IM, and old age.

The EZ-STEP H. pylori stool antigen test (Dinona Inc., Seoul, Korea) had a sensitivity of 93.1%, and specificity of 94.6% and was accurate 93.8% of the time. The sensitivity of histology, rapid urease test, and the 13C-urea breath test ranged from 89.1% to 97.6%, and their specificity was greater than 98%. The serological test, an enzyme-linked immunosorbent assay, identified as the H. pylori IgG EIA Well (Radim diagnostics, Rome, Italy) had high sensitivity, but low specificity. The stool antigen test still showed good diagnostic performance in the setting of progression of AG/IM and in patients over 40 years.

The authors concluded that the diagnostic performance of the new polyclonal stool antigen EIA was comparable to that of other methods used in the diagnosis of H. pylori infection in the screening population if an optimal cut-off value was determined. The stool antigen test might still be effective for the detection of H. pylori in the clinical settings of AG and/or IM and elderly patients. The study was published in June 2011, in the Journal of Gastroenterology and Hepatology.

Related Links:
Seoul National University
Radim diagnostics



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.